Peginterferon beta-1a
| Clinical data | |
|---|---|
| Trade names | Plegridy, Plegridy Pen |
| Other names | BIIB-017 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614059 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C913H1417N246O256PS7 [C2H4O]n |
| Molar mass | 44000 g·mol−1 |
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.[4][5]
The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.[4][5]
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.[6][5]
Medical uses
[edit]In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[4]
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[5]
References
[edit]- ^ "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Retrieved 25 June 2020.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
- ^ a b c d "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020.
- ^ a b c d e "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499". U.S. Food and Drug Administration (FDA). 17 September 2014. Retrieved 25 June 2020.
External links
[edit]- Plegridy at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
| Endogenous |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exogenous | |||||||||||||
| By family |
| ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| By function/ cell | |||||||||||||||||||||||||||||||||||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
